Skip to content
Tuesday, October 3, 2023
Latest:
  • Menarini strengthens its presence in aesthetic dermatology in India
  • Rusan Med’s thought-provoking webinar marks ‘Pain Awareness Month’ with expert insights and innovative solutions
  • A Shift to Non-Combustible Tobacco Devices Results in a Smoking Rate Decline by an Average of 5.2%: Says Expert
  • Eyesafe Introduces the World’s Strongest Blue Light Filtration Technology
  • Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World’s Largest Extracorporeal Life Support Conference
Healthcare Mumbai

Healthcare Mumbai

Mumbai's leading Healthcare News Portal

  • Mental Health
  • Health-Tech
  • Doctors & Hospitals
  • Labs & Diagnostics
  • Covid-19
  • Authored Articles
  • Press Announcements

Pharmaceuticals

Menarini strengthens its presence in aesthetic dermatology in India Pharmaceuticals

Menarini strengthens its presence in aesthetic dermatology in India

September 29, 2023September 29, 2023Jonas AasenLeave a Comment on Menarini strengthens its presence in aesthetic dermatology in India
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat Pharmaceuticals

Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

September 28, 2023September 28, 2023Karin EriksenLeave a Comment on Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials Pharmaceuticals

Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials

September 28, 2023September 28, 2023Åse KnutsenLeave a Comment on Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials
Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights Pharmaceuticals

Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights

September 26, 2023September 26, 2023Sofie LarsenLeave a Comment on Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights
WuXi Vaccines Launches Its First Vaccines CDMO Site in China Pharmaceuticals

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

September 26, 2023September 26, 2023Åse KnutsenLeave a Comment on WuXi Vaccines Launches Its First Vaccines CDMO Site in China
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services Pharmaceuticals

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services

September 26, 2023September 26, 2023Erik JohansenLeave a Comment on MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Pharmaceuticals

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

September 26, 2023September 26, 2023Anette NilsenLeave a Comment on RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC Pharmaceuticals

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

September 26, 2023September 26, 2023Anette NilsenLeave a Comment on Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan Pharmaceuticals

‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan

September 26, 2023September 26, 2023Leif KristoffersenLeave a Comment on ‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology Pharmaceuticals

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

September 25, 2023September 25, 2023Henrik OlsenLeave a Comment on Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
  • ← Previous
Top Picks
  • Menarini strengthens its presence in aesthetic dermatology in India
  • Rusan Med’s thought-provoking webinar marks ‘Pain Awareness Month’ with expert insights and innovative solutions
  • A Shift to Non-Combustible Tobacco Devices Results in a Smoking Rate Decline by an Average of 5.2%: Says Expert
  • Eyesafe Introduces the World’s Strongest Blue Light Filtration Technology
  • Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World’s Largest Extracorporeal Life Support Conference
  • Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
  • ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
  • Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials
Powered By: WordPress | Theme: MagazineBook By OdieThemes
Copyright © 2023 Healthcare Mumbai. All Rights Reserved | Powered by Trade News Network (A division of Thought Process Communications LLP)

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Healthcare Mumbai
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.